Literature DB >> 2296035

5-[(Aminoalkyl)amino]imidazo[4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity.

W M Cholody1, S Martelli, J Paradziej-Lukowicz, J Konopa.   

Abstract

A new class of antineoplastic agents, the 5-substituted imidazo[4,5,1-de]acridin-6-ones with an (aminoalkyl)amino group in the side chain, has been made. These compounds were synthesized by reduction of 1-substituted 4-nitroacridin-9(10H)-ones and subsequent reaction of the derived amines with carboxylic acids. Their cytotoxic activity against HeLaS3 cells in tissue culture and in vivo antitumor activity against P388 leukemia in mice was demonstrated. A strict relationship between the antineoplastic activity and the number of methylene spacers between proximal and distal nitrogens in the side chain was established.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296035     DOI: 10.1021/jm00163a009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.

Authors:  Ewa Augustin; Anna Skwarska; Anna Weryszko; Iwona Pelikant; Ewa Sankowska; Barbara Borowa-Mazgaj
Journal:  Acta Pharmacol Sin       Date:  2015-02-02       Impact factor: 6.150

2.  Metabolic transformation of antitumor acridinone C-1305 but not C-1311 via selective cellular expression of UGT1A10 increases cytotoxic response: implications for clinical use.

Authors:  Monika Pawlowska; Rong Chu; Barbara Fedejko-Kap; Ewa Augustin; Zofia Mazerska; Anna Radominska-Pandya; Timothy C Chambers
Journal:  Drug Metab Dispos       Date:  2012-11-16       Impact factor: 3.922

3.  Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Authors:  Barbara Fedejko-Kap; Stacie M Bratton; Moshe Finel; Anna Radominska-Pandya; Zofia Mazerska
Journal:  Drug Metab Dispos       Date:  2012-06-01       Impact factor: 3.922

4.  CYP3A4 overexpression enhances apoptosis induced by anticancer agent imidazoacridinone C-1311, but does not change the metabolism of C-1311 in CHO cells.

Authors:  Monika Pawłowska; Ewa Augustin; Zofia Mazerska
Journal:  Acta Pharmacol Sin       Date:  2013-12-02       Impact factor: 6.150

5.  Imidazoacridinone derivatives as efficient sensitizers in photoantimicrobial chemotherapy.

Authors:  Aleksandra Taraszkiewicz; Mariusz Grinholc; Krzysztof P Bielawski; Anna Kawiak; Joanna Nakonieczna
Journal:  Appl Environ Microbiol       Date:  2013-04-05       Impact factor: 4.792

6.  Absorption and luminescence spectroscopic analysis of tautomeric forms of protonatedN,N-dimethyl-N'-(1-nitro-9-acridinyl)-1,3-propanediamine (nitracrine) and its nitro isomers in poly(vinyl alcohol) films.

Authors:  J Rak; K Nowaczyk; J Blazejowski; A Kawski
Journal:  J Fluoresc       Date:  1991-03       Impact factor: 2.217

7.  Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer.

Authors:  A M Burger; J A Double; J Konopa; M C Bibby
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.

Authors:  A Skladanowski; J Konopa
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

9.  Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311.

Authors:  A M Burger; T C Jenkins; J A Double; M C Bibby
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  Photodynamic Inactivation of Candida albicans with Imidazoacridinones: Influence of Irradiance, Photosensitizer Uptake and Reactive Oxygen Species Generation.

Authors:  Aleksandra Taraszkiewicz; Grzegorz Szewczyk; Tadeusz Sarna; Krzysztof P Bielawski; Joanna Nakonieczna
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.